StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.10−0.01 (-0.47%)

Close on Nov 18, 2026Market cap $213.66MP/E –Yield –

AC Immune r&d expenses

Research and development expenses are spending on new products and technology.

AC Immune's R&D Expenses for the twelve months ending Dec 31, 2022 was CHF 60.34M, down 3.1% year over year. For fiscal 2025 it was CHF 56.44M, down 9.8% from the year before. Over ten years it grew 12.7% a year on average. The highest annual figure on record is CHF 62.57M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 56.44M-9.8%
FY2024Dec 31, 2024CHF 62.57M+14.6%
FY2023Dec 31, 2023CHF 54.61M-9.5%
FY2022Dec 31, 2022CHF 60.34M-3.1%
FY2021Dec 31, 2021CHF 62.28M+4.7%
FY2020Dec 31, 2020CHF 59.49M+18.0%
FY2019Dec 31, 2019CHF 50.43M+13.9%
FY2018Dec 31, 2018CHF 44.28M+35.6%
FY2017Dec 31, 2017CHF 32.66M+26.7%
FY2016Dec 31, 2016CHF 25.77M+51.2%
FY2015Dec 31, 2015CHF 17.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025CHF 16.83M+17.0%
Q2 FY2024Jun 30, 2024CHF 17.14M+9.2%
Q2 FY2023Jun 30, 2023CHF 13.68M-32.0%
Q4 FY2022Dec 31, 2022CHF 15.14M+0.1%
Q3 FY2022Sep 30, 2022CHF 14.39M+18.6%
Q2 FY2022Jun 30, 2022CHF 15.69M+35.9%
Q4 FY2021Dec 31, 2021CHF 20.12M+91.1%
Q3 FY2021Sep 30, 2021CHF 15.12M+50.1%
Q4 FY2018Dec 31, 2018CHF 12.13M+19.2%
Q3 FY2018Sep 30, 2018CHF 11.55M+40.9%
Q2 FY2018Jun 30, 2018CHF 10.53M+54.0%
Q1 FY2018Mar 31, 2018CHF 10.07M+35.1%
Q4 FY2017Dec 31, 2017CHF 10.18M–
Q3 FY2017Sep 30, 2017CHF 8.20M–
Q2 FY2017Jun 30, 2017CHF 6.84M–
Q1 FY2017Mar 31, 2017CHF 7.45M–

More AC Immune figures

See a number that looks wrong?